Related Experiment Video
Updated: Aug 31, 2025
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Novel Lung Growth Strategy with Biological Therapy Targeting Airway Remodeling in Childhood Bronchial Asthma
Mitsuru Tsuge1, Masanori Ikeda2, Hirokazu Tsukahara3
1Department of Pediatric Acute Diseases, Okayama University Academic Field of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama 700-8558, Japan.
Insights
Early asthma treatment with inhaled steroids and biologics may improve lung function and prevent adult COPD. Suppressing airway inflammation in childhood is key to long-term respiratory health.
Area of Science:
- Pediatric pulmonology
- Respiratory medicine
- Immunology
Background:
- Childhood asthma, even in remission, can lead to persistent airway inflammation, impaired lung development, and increased risk of adult COPD.
- Current therapies like inhaled steroids manage symptoms but may not fully prevent long-term lung damage or airway remodeling.
- Severe pediatric asthma is often linked to T-helper 2 (Th2) cytokine pathways.
Purpose of the Study:
- To review the long-term lung function prognosis for childhood asthma and the associated risk of developing adult COPD.
- To discuss the pathophysiology of allergic airway inflammation and remodeling driven by Th2 cytokines.
- To explore the potential of biological drugs in suppressing airway remodeling and improving outcomes in severe childhood asthma.
Main Methods:
- Literature review focusing on childhood asthma prognosis, airway inflammation, remodeling, and the role of Th2 cytokines.
- Analysis of current therapeutic strategies, including inhaled steroids and biological agents targeting Th2 pathways.
- Discussion of the need for further clinical trials with advanced imaging to assess biological drug effects on airway remodeling.
Main Results:
- Childhood asthma negatively impacts lung maturation and function, increasing COPD risk later in life.
- Biological drugs targeting Th2 cytokines show promise in reducing exacerbations and inflammation in severe pediatric asthma.
- Evidence for biological drugs suppressing airway remodeling in childhood asthma is currently lacking, necessitating further research.
Conclusions:
- Early and aggressive suppression of airway inflammation in childhood asthma is crucial for optimizing lung function and preventing adult COPD.
- Biological therapies offer a potential avenue for mitigating airway remodeling and improving long-term respiratory health in children with severe asthma.
- Further investigation, particularly using airway imaging, is required to confirm the efficacy of biological drugs against airway remodeling in pediatric asthma.
Abstract:
Anti-inflammatory therapy, centered on inhaled steroids, suppresses airway inflammation in asthma, reduces asthma mortality and hospitalization rates, and achieves clinical remission in many pediatric patients. However, the spontaneous remission rate of childhood asthma in adulthood is not high, and airway inflammation and airway remodeling persist after remission of asthma symptoms. Childhood asthma impairs normal lung maturation, interferes with peak lung function in adolescence, reduces lung function in adulthood, and increases the risk of developing chronic obstructive pulmonary disease (COPD). Early suppression of airway inflammation in childhood and prevention of asthma exacerbations may improve lung maturation, leading to good lung function and prevention of adult COPD. Biological drugs that target T-helper 2 (Th2) cytokines are used in patients with severe pediatric asthma to reduce exacerbations and airway inflammation and improve respiratory function. They may also suppress airway remodeling in childhood and prevent respiratory deterioration in adulthood, reducing the risk of COPD and improving long-term prognosis. No studies have demonstrated a suppressive effect on airway remodeling in childhood severe asthma, and further clinical trials using airway imaging analysis are needed to ascertain the inhibitory effect of biological drugs on airway remodeling in severe childhood asthma. In this review, we describe the natural prognosis of lung function in childhood asthma and the risk of developing adult COPD, the pathophysiology of allergic airway inflammation and airway remodeling via Th2 cytokines, and the inhibitory effect of biological drugs on airway remodeling in childhood asthma.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...